01 7Anoro Ellipta
02 8Incruse Ellipta
03 5Trelegy Ellipta
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 758
2019 Revenue in Millions : 713
Growth (%) : 6
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 1,135
2019 Revenue in Millions : 718
Growth (%) : 58
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 305
2019 Revenue in Millions : 363
Growth (%) : -16
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 277
2020 Revenue in Millions : 301
Growth (%) : -7
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 1,647
2020 Revenue in Millions : 1,122
Growth (%) : 49
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 682
2020 Revenue in Millions : 749
Growth (%) : -8
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 2,132
2021 Revenue in Millions : 1,647
Growth (%) : 29
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 242
2021 Revenue in Millions : 277
Growth (%) : -13
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 595
2021 Revenue in Millions : 682
Growth (%) : -13
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2023 Revenue in Millions : 175
2022 Revenue in Millions : 242
Growth (%) : -17
